Alex Fotopoulos
Technik-/Wissenschafts-/F&E-Leiter bei PASSAGE BIO, INC.
Vermögen: 96 005 $ am 30.04.2024
Aktive Positionen von Alex Fotopoulos
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| PASSAGE BIO, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2019 | - |
Karriereverlauf von Alex Fotopoulos
Ehemalige bekannte Positionen von Alex Fotopoulos
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2017 | 01.07.2019 |
| DIMENSION THERAPEUTICS INC | Technik-/Wissenschafts-/F&E-Leiter | 01.05.2016 | 01.11.2017 |
| MOMENTA PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.08.2011 | 01.05.2016 |
| BIOGEN INC. | Corporate Officer/Principal | 01.08.1994 | 01.01.2011 |
Ausbildung von Alex Fotopoulos
| Tufts University | Graduate Degree |
| F.W. Olin Graduate School of Business | Masters Business Admin |
Statistik
International
| Vereinigte Staaten | 8 |
Operativ
| Chief Tech/Sci/R&D Officer | 4 |
| Graduate Degree | 1 |
| Masters Business Admin | 1 |
Sektoral
| Health Technology | 6 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| PASSAGE BIO, INC. | Health Technology |
| ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
| BIOGEN INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Dimension Therapeutics, Inc.
 Dimension Therapeutics, Inc. BiotechnologyHealth Technology Dimension Therapeutics, Inc. engages in the development of novel treatments for rare diseases. Its activities include discoveries and development of therapeutic products for people living with rare diseases associated wit the liver and caused by genetic mutations. The company was founded by Ben Auspitz in June 20, 2013 and is headquartered in Cambridge, MA. | Health Technology |
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Alex Fotopoulos
- Erfahrung
